Regeneron Pharmaceuticals
REGN
576 hedge funds and large institutions have $26.3B invested in Regeneron Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 92 funds opening new positions, 220 increasing their positions, 180 reducing their positions, and 55 closing their positions.
69.35% more ownership
Funds ownership: 0% → 69.35% (+69%)
67% more first-time investments, than exits
New positions opened: 92 | Existing positions closed: 55
22% more repeat investments, than reductions
Existing positions increased: 220 | Existing positions reduced: 180
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
4% more funds holding
Funds holding: 553 → 576 (+23)
10% less call options, than puts
Call options by funds: $732M | Put options by funds: $814M
10% less capital invested
Capital invested by funds: $29.4B → $26.3B (-$3.08B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$216M |
| 2 |
Polen Capital Management
Boca Raton,
Florida
|
+$201M |
| 3 |
MNA
Manning & Napier Advisors
Fairport,
New York
|
+$167M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$98M |
| 5 |
Renaissance Technologies
New York
|
+$95.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$498M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$483M |
| 3 |
JP Morgan Chase
New York
|
-$265M |
| 4 |
Goldman Sachs
New York
|
-$221M |
| 5 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$94.4M |
REGN Hedge Fund Activity: Q4 2016 in Review
576 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2016, worth a combined $26.3B — down 10% from $29.4B a quarter earlier.
Buyers outnumbered sellers: 92 funds opened new REGN positions and 55 closed out — a net gain of 37 holders — while 220 added to existing stakes and 180 trimmed.
The largest buyer was Loomis, Sayles & Company, adding an estimated $216M. The largest seller was Fidelity Investments, cutting an estimated $498M.
- 576 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2016, up from 553 in Q3 2016.
- Funds reported $26.3B of Regeneron Pharmaceuticals stock for Q4 2016, down 10% quarter-over-quarter.
- 92 funds opened new Regeneron Pharmaceuticals positions in Q4 2016 and 55 closed out, a net change of +37 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2016 was Loomis, Sayles & Company, an estimated $216M added.
- The largest Regeneron Pharmaceuticals seller in Q4 2016 was Fidelity Investments, an estimated $498M sold.
Based on aggregated 13F filings for Q4 2016.